Boston Pharmaceuticals   Report issue

Contributed to NME For profit Phase 1 Phase 2
Founded: Cambridge MA United States (2015)

Organization Overview

First Clinical Trial
2017
NCT03036865
First Marketed Drug
2021
dexmethylphenidate (focalin)
First NDA Approval
2021
serdexmethylphenidate (AZSTARYS)
Last Known Activity
2021

Timeline

NOW
  • Now

Alternative names

Boston Pharmaceuticals | Boston Pharmaceuticals, Vice President, Clinical Development | COMMAVE THERAP

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acne Vulgaris (Phase 1)

Diarrhea (Phase 2)

Irritable Bowel Syndrome (Phase 2)

Lupus Erythematosus, Systemic (Phase 2)

Neoplasms (Phase 1)

Psoriasis (Phase 1)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 11
  • # of Trial APIs: 12